Healthcare / BiotechnologyNasdaqCM
$2.18
+0.03 (+1.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-18.9M · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$9M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-205.3%
↓Gross Margin
N/A
•Debt/Equity
0.14
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-14.5M · FCF $-14.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | — | — | — | — | $500000.00 | $500000.00 | $500000.00 | $500000.00 | $500000.00 | $500000.00 | — | — | — | — | — | — | — |
| Net Income | $-14.5M | $-14.5M | $-18.6M | $-19.5M | $-35.9M | $-20.8M | $-21.5M | $-16.9M | $-11.9M | $-20.4M | $-22.1M | $-22.5M | $-25.5M | $-8.3M | $-26.6M | $-23.2M | $-18.8M |
| EBITDA | $-14.0M | $-14.0M | $-18.4M | $-19.9M | $-31.7M | $-20.3M | $-17.7M | $-19.8M | $-20.7M | $-17.9M | $-19.6M | $-20.4M | $-24.3M | $-15.1M | $-21.9M | $-22.8M | $-19.5M |
| EPS | -6.83 | -6.83 | -21.13 | -28.17 | -65.61 | -49.96 | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | -4984.3% | -4201.4% | -3697.3% | -4113.1% | -4213.0% | -3693.7% | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | -7179.6% | -4153.9% | -4296.7% | -3370.3% | -2376.7% | -4080.4% | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 0.14 | 0.14 | 0.27 | 0.12 | 0.21 | — | 0.27 | 0.67 | 0.45 | — | — | — | — | 0.16 | 0.42 | — | — |
| Current Ratio | 1.59 | 1.59 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-14.2M | $-14.2M | $-18.9M | $-19.5M | $-23.4M | $-16.5M | $-15.6M | $-20.6M | $-7.2M | $-16.7M | $-18.4M | $-20.9M | $-22.0M | $-9.6M | $-22.8M | $-23.3M | $-13.4M |
| Returns | |||||||||||||||||
| ROE | -205.3% | -205.3% | -438.7% | -145.8% | -122.4% | -37.2% | -115.4% | -115.7% | -57.0% | -76.4% | -327.9% | -110.2% | -77.7% | -26.2% | -222.1% | -88.7% | 411.3% |
| Valuation | |||||||||||||||||
| P/B | 0.66 | 0.66 | 2.77 | 0.47 | 0.39 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| EPS Growth | 67.7% | 67.7% | 25.0% | 57.1% | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-93.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-21.13 → -6.83
Residual
-93.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.